Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
Sunshine Biopharma (SBFM, SBFMW) has filed a provisional patent application in the U.S. for mRNA molecules shown to effectively target cancer cells in pre-clinical trials. The mRNA demonstrated minimal toxicity to normal human cells while exhibiting cytotoxicity against various cancer types, including multidrug resistant breast and pancreatic cancer. Additionally, the company is enhancing its COVID-19 treatment research, having synthesized potential inhibitors and secured a collaboration with the University of Arizona. Clinical trials for its anticancer compound Adva-27a are planned at a Montreal hospital.
- Filed a provisional patent for mRNA molecules targeting cancer cells.
- mRNA demonstrated effectiveness against multidrug resistant breast and pancreatic cancer with low toxicity to normal cells.
- Entered collaboration with the University of Arizona to develop COVID-19 inhibitors.
- Planned clinical trials for Adva-27a at McGill University’s Jewish General Hospital.
- None.
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.
The cytotoxic effects of the subject mRNA molecules were tested on different cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). In contrast to cancer cells, the mRNA molecules had little cytotoxic effects on non-transformed (normal) human cells (HMEC cells). These mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology.
“We are excited about this potential intellectual property position we just staked in connection with our ongoing mRNA-as-therapeutic-agents research,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We believe the potential use of mRNA to treat human diseases opens the door to vast therapeutic possibilities for patients,“ he added.
About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 6.2 million people worldwide since it first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. In addition, the Company recently expanded its research efforts into finding other PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. The Company holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the research project.
In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Cautionary Note Regarding Forward Looking Statements
This press release and statements of the Company's management made in connection therewith contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as "may", "could", "expects", "projects," "intends", "plans", "believes", "predicts", "anticipates", "hopes", "estimates" and variations of such words and similar expressions are intended to identify forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company's control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in the Company's filings with the SEC. The Company's SEC filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Sunshine Biopharma, Inc. (the “Company”) expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
For Additional Information:
Sunshine Biopharma Media Contacts:
TraDigital IR
Direct Line: 917-633-8980
investors@sunshinebiopharma.com
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
FAQ
What is Sunshine Biopharma's recent patent application about?
What cancers are targeted by the mRNA molecules from Sunshine Biopharma?
What collaborations has Sunshine Biopharma engaged in for COVID-19 treatment?
Where are the clinical trials for Adva-27a planned?
